CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D000072656: Breast Cancer Lymphedema NIH

(Synonyms: Breast Cancer Lymphed, Breast Cancer Lymphedema)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)


Name (Synonyms) Correlation
drug1246 High Intensity Interval Training group Wiki 1.00
drug1118 Flexitouch Plus with Cellular Connectivity (FT-CC) Wiki 1.00
drug3146 Yoga group Wiki 1.00
drug714 Combination Wiki 1.00

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D008209 Lymphedema NIH 1.00
D001943 Breast Neoplasms NIH 0.50

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0001004 Lymphedema HPO 1.00
HP:0003002 Breast carcinoma HPO 0.50

There is one clinical trial.

Clinical Trials


1 A Feasibility Study Evaluating the Impact Flexitouch Plus With Connectivity Has on Compliance in Patients With Breast Cancer-Related Lymphedema (BCRL)

The objective of this study is to demonstrate the feasibility of using the Flexitouch Plus with Cellular Connectivity (FT-CC) to monitor device use data to determine if reminders to patients impact compliance, and to identify the impact device compliance has on arm girth, quality of life (QOL), and symptom assessment.

NCT04432727 Breast Cancer Lymphedema Device: Flexitouch Plus with Cellular Connectivity (FT-CC)
MeSH:Breast Neoplasms Lymphedema Breast Cancer Lymphedema
HPO:Breast carcinoma Lymphedema Neoplasm of the breast

Primary Outcomes

Description: Compare the rate of compliance (defined as the number of days device used/total study days) in patients treated with PASSIVE FT-CC and ACTIVE FT-CC.

Measure: Compliance

Time: Changes between 30 days after device training and 60 days after device training

Secondary Outcomes

Description: Comparison of partially compliant and compliant arm girth in patients treated with FT-CC. Arm girth is measured in cm.

Measure: Change in Arm Girth

Time: Changes between baseline, 30 days after device training, and 60 days after device training

Description: Comparison of partially compliant and compliant quality of life in patients treated with FT-CC via Lymphedema Quality of Life Tool (LYMQOL ARM). Lymphedema Quality of Life Tool (LYMQOL-ARM) includes sub-scores for Function (range 10-40), Appearance (range 5-20), Symptoms (range 6-24), and Emotion (range 6-24) where lower scores represent a better outcome. It also includes an Overall QOL sub-score (range 0-10) where a higher score represents a better outcome.

Measure: Quality of Life Assessment via LYMQOL ARM

Time: Changes between baseline, 30 days after device training, and 60 days after device training

Description: Comparison of partially compliant and compliant quality of life in patients treated with FT-CC by via The RAND 36-Item Short Form Survey (SF-36). The RAND 36-Item Short Form Survey (SF-36) taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item for perceived change in health. Min value: 0, Max value: 100. Higher scores represent a better outcome.

Measure: Quality of Life Assessment via SF-36

Time: Changes between baseline, 30 days after device training, and 60 days after device training

Description: Comparison of partially compliant and compliant symptoms in patients treated with FT-CC by via The Lymphedema Symptom Intensity and Distress Survey-ARM (LSIDS-A). The Lymphedema Symptom Intensity and Distress Survey is a questionnaire used to assess intensity and distress of symptoms in patients with lymphedema of the arm. This includes sub-scores for soft tissue sensation (range 0-10), neurological sensation (0-10), function, (0-10), biobehavioral (0-10), resource (0-10), sexuality (0-10), activity (0-10). Higher score represents worse outcome.

Measure: Symptoms Assessment via LSIDS-A

Time: Changes between baseline, 30 days after device training, and 60 days after device training


HPO Nodes